Medtronic (NYSE:MDT) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Medtronic (NYSE:MDT) from a hold rating to a buy rating in a report published on Saturday,Wall Street Zen reports.

MDT has been the subject of several other reports. Weiss Ratings upgraded shares of Medtronic from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, September 4th. UBS Group lifted their target price on shares of Medtronic from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, September 3rd. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research note on Monday, August 10th. Truist Financial reiterated a “hold” rating and set a $99.00 price target (up from $86.00) on shares of Medtronic in a research report on Wednesday, September 2nd. Finally, Needham & Company LLC reissued a “buy” rating on shares of Medtronic in a research note on Thursday, September 17th. Nineteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Medtronic has a consensus rating of “Moderate Buy” and a consensus target price of $103.92.

Medtronic Price Performance

Shares of MDT stock opened at $86.31 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. Medtronic has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The firm has a market cap of $110.40 billion, a P/E ratio of 21.26, a P/E/G ratio of 1.97 and a beta of 0.55. The business’s 50 day moving average price is $90.15 and its 200-day moving average price is $84.79.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The company had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. During the same quarter in the prior year, the company earned $1.26 earnings per share. The firm’s revenue for the quarter was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities research analysts anticipate that Medtronic will post 5.98 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 annualized dividend and a yield of 3.3%. Medtronic’s dividend payout ratio (DPR) is currently 70.94%.

Insider Activity at Medtronic

In other news, EVP Harry Kiil sold 1,483 shares of the company’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the sale, the executive vice president directly owned 42,186 shares of the company’s stock, valued at $3,950,718.90. This represents a 3.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. First Citizens Financial Corp bought a new stake in Medtronic during the third quarter worth about $201,000. Versant Capital Management Inc grew its holdings in Medtronic by 95.6% in the third quarter. Versant Capital Management Inc now owns 7,465 shares of the medical technology company’s stock worth $644,000 after purchasing an additional 3,649 shares during the period. First Financial Bank Trust Division increased its stake in shares of Medtronic by 4.3% during the third quarter. First Financial Bank Trust Division now owns 37,197 shares of the medical technology company’s stock valued at $3,210,000 after purchasing an additional 1,540 shares in the last quarter. Stonebridge Financial Group LLC increased its stake in shares of Medtronic by 0.4% during the third quarter. Stonebridge Financial Group LLC now owns 54,227 shares of the medical technology company’s stock valued at $4,679,000 after purchasing an additional 217 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. increased its stake in shares of Medtronic by 17.4% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 73,993 shares of the medical technology company’s stock valued at $5,788,000 after purchasing an additional 10,960 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: TD Cowen reiterated a “Buy” rating on Medtronic, providing an analyst-confidence signal for the medical-device maker. Medtronic Earns Buy Rating from TD Cowen
• Positive Sentiment: The FDA granted breakthrough-device designation to Medtronic’s below-the-knee drug-coated balloon, potentially accelerating regulatory interaction and supporting the company’s peripheral vascular pipeline. Medtronic Receives Breakthrough Designation
• Positive Sentiment: The American Medical Association approved Category I CPT codes for the Altaviva tibial neuromodulation device and Symplicity Spyral renal-denervation system. The codes become effective in January 2028 and could improve reimbursement visibility and adoption over the long term. Medtronic CPT Code Approvals
• Positive Sentiment: New regulatory clearances for cardiac mapping and ablation software may strengthen Medtronic’s competitive position in the growing pulsed-field ablation market. Medtronic Cardiac Software Clearances
• Neutral Sentiment: A commentary argues that Medtronic’s dividend and defensive healthcare exposure could remain attractive if inflation and interest rates stay elevated, but it does not represent a new company-specific catalyst. Inflation and Dividend Stocks
• Neutral Sentiment: An investment opinion says Medtronic’s long-term strategy could still appeal to investors, although Johnson & Johnson’s stronger historical performance highlights execution concerns. Johnson and Johnson Compared With Medtronic
• Negative Sentiment: The $4 billion tax-free MiniMed exchange offer appears to be losing investor appeal. Reduced participation could make the split-off a weaker near-term catalyst and leave shareholders focused on execution and valuation risks. Medtronic MiniMed Exchange Offer
• Negative Sentiment: Medtronic’s stock has declined since its latest earnings report, with investors apparently looking for stronger forward earnings momentum despite the prior quarterly revenue and EPS beat. Medtronic Stock Since Earnings
• Negative Sentiment: Put-option volume was about 45% above average, indicating increased downside hedging or bearish positioning around MDT.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.